<?xml version="1.0" encoding="UTF-8"?><rss version="2.0"
	xmlns:content="http://purl.org/rss/1.0/modules/content/"
	xmlns:wfw="http://wellformedweb.org/CommentAPI/"
	xmlns:dc="http://purl.org/dc/elements/1.1/"
	xmlns:atom="http://www.w3.org/2005/Atom"
	xmlns:sy="http://purl.org/rss/1.0/modules/syndication/"
	xmlns:slash="http://purl.org/rss/1.0/modules/slash/"
	>

<channel>
	<title>Affective disorder &#8211; European Clinical Trials Information Network</title>
	<atom:link href="https://clinicaltrials.eu/meddra_pt/affective-disorder/feed/" rel="self" type="application/rss+xml" />
	<link>https://clinicaltrials.eu</link>
	<description>Bridging Patients with Clinical Trials</description>
	<lastBuildDate>Fri, 12 Jun 2026 10:35:06 +0000</lastBuildDate>
	<language>en-US</language>
	<sy:updatePeriod>
	hourly	</sy:updatePeriod>
	<sy:updateFrequency>
	1	</sy:updateFrequency>
	<generator>https://wordpress.org/?v=7.0</generator>

<image>
	<url>https://clinicaltrials.eu/wp-content/uploads/2024/12/cropped-EU_icon-32x32.png</url>
	<title>Affective disorder &#8211; European Clinical Trials Information Network</title>
	<link>https://clinicaltrials.eu</link>
	<width>32</width>
	<height>32</height>
</image> 
	<item>
		<title>Study on Personalized Dosing of Sertraline, Aripiprazole, and Risperidone for Patients with Mood, Anxiety, or Psychotic Disorders</title>
		<link>https://clinicaltrials.eu/trial/study-on-personalized-dosing-of-sertraline-aripiprazole-and-risperidone-for-patients-with-mood-anxiety-or-psychotic-disorders/</link>
		
		<dc:creator><![CDATA[]]></dc:creator>
		<pubDate>Wed, 29 Apr 2026 14:58:04 +0000</pubDate>
				<guid isPermaLink="false">https://clinicaltrials.eu/trial/study-on-personalized-dosing-of-sertraline-aripiprazole-and-risperidone-for-patients-with-mood-anxiety-or-psychotic-disorders/</guid>

					<description><![CDATA[This clinical trial is focused on studying the effects of certain medications on individuals with various mental health conditions. The diseases being studied include major depressive disorder, bipolar disorder (currently in a depressive episode), anxiety disorders such as panic disorder and generalized anxiety disorder, and psychotic disorders like schizophrenia and schizoaffective disorder. The medications involved [&#8230;]]]></description>
										<content:encoded><![CDATA[<p>This clinical trial is focused on studying the effects of certain medications on individuals with various mental health conditions. The diseases being studied include <i>major depressive disorder</i>, <i>bipolar disorder</i> (currently in a depressive episode), <i>anxiety disorders</i> such as panic disorder and generalized anxiety disorder, and <i>psychotic disorders</i> like schizophrenia and schizoaffective disorder. The medications involved in this study are <i>sertraline</i>, <i>escitalopram</i>, <i>aripiprazole</i>, and <i>risperidone</i>. These medications are commonly used to treat mood, anxiety, and psychotic disorders.</p>
<p>The purpose of the study is to compare how well patients respond to medication doses that are personalized based on their genetic makeup, known as pharmacogenetics, versus the usual dosing methods. Participants will be randomly assigned to receive either the personalized dosing or the usual dosing, which may include a placebo. The study will last for 24 weeks, during which participants will take the medication orally in the form of tablets. Throughout the study, participants&#8217; recovery, well-being, and quality of life will be monitored, along with any side effects they may experience.</p>
<p>Pharmacogenetics is a field of medicine that looks at how a person&#8217;s genes can affect their response to drugs. By understanding these genetic differences, doctors can tailor treatments to each individual, potentially improving the effectiveness of the medication and reducing side effects. This study aims to see if using pharmacogenetics can lead to better outcomes for patients with these mental health conditions.</p>
]]></content:encoded>
					
		
		
			</item>
	</channel>
</rss>
